Roche Q1 sales fall 5% to CHF 14.7B

 F. Hoffmann-La Roche AG said its group sales reached CHF 14.7 billion in the first quarter of 2026, rising 6% at constant exchange rates (CER) but falling 5% in CHF.

Sales in the pharmaceuticals division came in at CHF 11.5 billion, rising 7% at CER but declining 4% in CHF, driven by demand for key medicines including Xolair, Phesgo, Hemlibra, Vabysmo and Ocrevus. Diagnostics sales stood at CHF 3.3 billion, increasing 3% at CER but falling 7% in CHF, as growth in core lab and pathology solutions offset pricing pressure in China.

"We delivered a strong start to the year, achieving 6% Group sales growth at constant exchange rates," Chief Executive Thomas Schinecker said. "Our pipeline continued to advance in areas where patients face significant unmet need, including multiple sclerosis, obesity and a severe autoimmune disease that can lead to kidney failure," he added, noting the company confirmed its full-year outlook.

https://breakingthenews.net/Article/Roche-Q1-sales-fall-5-to-CHF-14.7B/66130194